Type 2 Diabetes
Type 2 diabetes (T2D) is a chronic condition characterized by high blood sugar levels due to insulin resistance and an insufficient production of insulin by the pancreas. Common symptoms include increased thirst, frequent urination, fatigue, and potential long-term complications like heart disease, kidney failure, and neuropathy, though lifestyle changes and weight loss can effectively manage the disease.
Health Outcomes
- Activation of G-Protein Coupled Receptors
- Alleviated Intestinal Metabolic Disorders
- Alleviated Non-Alcoholic Fatty Liver Disease
- Altered Bifidobacterium Profile
- Altered Dominant Microbial Community
- Altered Metabolic Profile
- Altered Metabolite Profile
- Altered Microbial Composition
- Altered Microbial Phyla Abundance
- Altered NF-kappaB Signaling
- Altered Serum IL-6 Levels
- Altered Spermidine Levels
- Association with Sarcopenia
- Atherogenic Lipid Profile
- Change in Waist-to-Hip Ratio
- Changed Clinical Chemistry Parameter
- Changed Leukocyte Telomere Length
- Changed Magnesium Level
- Changes in Health Status from Probiotic Intervention
- Changes in Inflammatory Markers
- Characterized Carbohydrate Metabolism Enzyme Activity
- Controlled Serum Cholesterol Levels
- Decreased Glycocholic Acid Levels in Older Women
- Decreased HDL Cholesterol Level
- Decreased Hafnia-Obesumbacterium Genus
- Decreased Prevotella Copri Relative Abundance
- Decreased Roseburia faecis Relative Abundance
- Decreased Uncarboxylated to Total Osteocalcin Ratio
- Delayed Cardiac Pathology
- Diabetes Progression
- Disease Prevention
- Distinct Metabolic Profile
- Elevated Insulin Levels
- Elevated Redox Status
- Elevated Serum TNF-α Levels
- Elevated Short Chain Fatty Acids (SCFAs) Levels
- Elevated Triglyceride Levels
- Enhanced Adverse Event Reporting
- Enhanced Antioxidant Bioaccessibility
- Enhanced Antioxidant Metabolism
- Enhanced Beneficial Gut Microbiota
- Enhanced Cell Viability Under Oxidative Stress
- Enhanced Endoplasmic Reticulum Stress Response
- Enhanced GLP-1 Response
- Enhanced Glycolysis Pathway Activation
- Enhanced Growth of Beneficial Gut Bacteria
- Enhanced Gut Microbiota
- Enhanced Insulin Secretion
- Enhanced Metabolic Function
- Enhanced Metabolic Pathway Activation
- Enhanced Metabolism of Organic Matter
- Enhanced Metabolite Levels
- Enhanced Polyphenol Levels
- Enhanced Serum Peroxidase Activity
- Enhanced TGR5 Signaling
- Enhanced Wound Healing
- Extended Lifespan in Caenorhabditis elegans
- Identification of FDA Approved Drug Target Regulators
- Improved 5000 m Running Time
- Improved Acceptability of Dairy Products
- Improved Adipokine Profile
- Improved Adipose Browning
- Improved Adiposity Biomarkers
- Improved Aerobic Capacity
- Improved Aerobic Endurance Performance
- Improved Aerobic Power
- Improved Aging-Related Changes
- Improved Anaerobic Power
- Improved Antioxidant Activity
- Improved ApoB-100/ApoA-1 Ratio
- Improved Atherosclerosis-Related Cardiovascular Risk Markers
- Improved Beta-Cell Function
- Improved Bioactivity
- Improved Blood Biochemical Parameter
- Improved Blood Clinical Chemistry
- Improved Blood Glucose Concentration
- Improved Blood Glucose Control
- Improved Blood Glucose Levels
- Improved Blood Lipid Profile
- Improved Blood Pressure
- Improved Body Mass Index
- Improved Carbohydrate Metabolism
- Improved Carbohydrate Oxidation
- Improved Cardiometabolic Health
- Improved Cholesterol Levels
- Improved Cholesterol Regulation
- Improved Clinical Outcome
- Improved Clinical Outcomes
- Improved Clinical Success
- Improved Corneal Nerve Reflectivity
- Improved Cycling Time Trial Performance
- Improved Diabetic Foot Ulcer Healing
- Improved Diabetic Nephropathy
- Improved Diabetic Retinopathy
- Improved Dialysis Adequacy
- Improved Disease Management
- Improved Diversity of Gut Microbiota
- Improved Dyslipidemia
- Improved Efficacy Rate
- Improved Endothelial Reactivity
- Improved Endothelium-Dependent Vasodilation
- Improved Endothelium-Independent Microvascular Vasodilation
- Improved Energy Metabolism in White Adipose Tissue
- Improved Estimated VO2max
- Improved Exercise Performance
- Improved Fasting Glucose Levels
- Improved Fasting Plasma Glucose
- Improved Fat Metabolism Regulation
- Improved Fatty Acid Oxidation
- Improved Flow-Mediated Dilation
- Improved Flow-Mediated Vasodilation
- Improved Free Radical Scavenging Activity
- Improved Gastrointestinal Hormone Regulation
- Improved General Health
- Improved General Health Perception
- Improved Glucose Homeostasis
- Improved Glucose Level
- Improved Glucose Metabolism
- Improved Glucose Regulation
- Improved Glucose Response
- Improved Glutathione Level
- Improved Glutathione Redox Ratio
- Improved Glycemia
- Improved Glycemic Control
- Improved Glycemic Response
- Improved Glycogen Synthetase Activity
- Improved Gut Microbial Alpha Diversity
- Improved Gut Microbiome Function
- Improved Gut Microbiota-Related Pathways
- Improved HbA1c
- Improved Health Condition
- Improved Health Markers
- Improved Health Outcomes
- Improved Health Perception
- Improved Health Status Score
- Improved Heart Rate Variability
- Improved Hemoglobin A1c Levels
- Improved Hepatic Insulin Sensitivity
- Improved High-Intensity Intermittent Exercise Performance
- Improved Hormonal Counter-Regulation
- Improved Human Health
- Improved Inflammatory Biomarkers
- Improved Insulin Levels
- Improved Insulin Resistance
- Improved Insulin Response
- Improved Insulin Secretion
- Improved Insulin Secretion Rate
- Improved Insulin Sensitivity
- Improved LDL Cholesterol
- Improved Lactate Threshold
- Improved Lifespan
- Improved Lipid Levels
- Improved Lipid Metabolism
- Improved Longevity
- Improved Lower Limb Peak Power
- Improved Lower-Body Muscular Strength
- Improved Maternal Metabolic Health
- Improved Maximal Exercise Capacity
- Improved Maximal Oxygen Capacity
- Improved Maximal Oxygen Uptake
- Improved Maximal Power
- Improved Maximal Walking Performance
- Improved Medication Adherence
- Improved Metabolic Activity of Bacillus coagulans
- Improved Metabolic Disease Markers
- Improved Metabolic Disorders
- Improved Metabolic Function
- Improved Metabolic Health
- Improved Metabolic Homeostasis
- Improved Metabolic Parameters
- Improved Metabolic Profile
- Improved Metabolic Regulation
- Improved Metabolic Syndrome Biomarkers
- Improved Metabolic Syndrome Remission
- Improved Metabolome Profile
- Improved Microbial Community Composition
- Improved Microbial Metabolism Regulation
- Improved Microflora Composition
- Improved Monocyte Activation
- Improved Muscular Endurance
- Improved NAFLD
- Improved Nutritional Metabolism
- Improved Obesity Metrics
- Improved Obesity Parameters
- Improved Overall Health
- Improved Oxidative Stress Biomarker
- Improved Oxidative Stress Marker
- Improved Patient Satisfaction
- Improved Physical Health-Related Quality of Life
- Improved Physical Quality of Life
- Improved Physical Role Limitation
- Improved Plasma Glucose Control
- Improved Plasma Lipid Levels
- Improved Post-Myocardial Infarction Outcome
- Improved Postprandial Glucose Levels
- Improved Protein Kinase C Activity
- Improved Protein Secretion
- Improved Quality of Life
- Improved Reactive Hyperemia Index
- Improved Redox Homeostasis
- Improved Retinal Function
- Improved Retinal Vascular Health
- Improved Retinopathy
- Improved Satiety Hormonal Status
- Improved Satiety Index
- Improved Satiety Response
- Improved Serum Biomarkers
- Improved Serum Glucose Levels
- Improved Serum Glycemia
- Improved Sprint Performance
- Improved Standing Balance
- Improved Stress-Strain Index
- Improved Superoxide Dismutase Activity
- Improved Superoxide Dismutase Level
- Improved Swimming Performance
- Improved Systemic Health
- Improved Systemic Metabolism
- Improved Total Antioxidant Capacity
- Improved Total Antioxidative Status
- Improved Total Cholesterol Levels
- Improved Treatment Efficacy
- Improved Triglyceride Levels
- Improved VLDL Cholesterol
- Improved VO2max
- Improved Weight Loss
- Improved Weight Management
- Improved Work Capacity
- Improved Yo-Yo Test Performance
- Increase in Beneficial Bifidobacterial Species
- Increased AMPK Activation
- Increased Acyl/Des-Acyl Ghrelin Ratio
- Increased Adiponectin Levels
- Increased Adipose Browning
- Increased Autophagy
- Increased Bacteroides ovatus Abundance
- Increased Beneficial Gut Bacteria
- Increased Bifidobacterial Counts
- Increased Bifidobacterium adolescentis Levels
- Increased Bifidobacterium longum Relative Abundance
- Increased Bioactivity
- Increased Birthweight
- Increased Blood Glucose Levels
- Increased Bmi1 Levels in Intestinal Epithelial Cells
- Increased Body Mass
- Increased Body Mass Index
- Increased Body Weight
- Increased Branched Chain Amino Acid Levels
- Increased Butyrate Levels
- Increased C-Reactive Protein Level
- Increased CD163+ Macrophage Density
- Increased CD68 to CD163 Ratio
- Increased Catalase Activity
- Increased Catalase Expression
- Increased Circulating 25-Hydroxyvitamin D Levels
- Increased Complement C3 Level
- Increased Cysteine Level
- Increased Daily Weight Gain
- Increased Diversity of Fecal Bifidobacterial Populations
- Increased ER Stress-Associated Proteins
- Increased Endogenous Acrolein Formation
- Increased Exercise Capacity
- Increased FNDC5 Concentration
- Increased Fasting Insulin Level
- Increased Fat Oxidation
- Increased Fecal Acetate Concentration
- Increased Fecal Bifidobacterium Count
- Increased Fecal Butyrate Levels
- Increased Femoral Neck Bone Mineral Density
- Increased GLP-1 Levels
- Increased GSH/GSSG Ratio
- Increased Glucagon-Like Peptide 1 Level
- Increased Glucose Uptake by Cells
- Increased Glucose Utilization During Feed Restriction
- Increased Glutathione Disulfide Ratio
- Increased Glutathione Level
- Increased Glutathione Peroxidase Level
- Increased Glycine Level
- Increased Glycolysis Pathway Activity
- Increased Gut Hormone Level
- Increased HDL Cholesterol Levels
- Increased High-Density Lipoprotein Cholesterol
- Increased Hormone-Sensitive Lipase Activity
- Increased Hydroxy Fatty Acid Level
- Increased Hyperkalemia
- Increased IL-6 Levels in Early Phase
- Increased IPA Levels
- Increased Infection Frequency
- Increased Inhibition of Lipid Oxidation
- Increased Insulin Level
- Increased Insulin Resistance Level
- Increased Insulin Response
- Increased Insulin Secretion
- Increased Intestinal Bifidobacterium Levels
- Increased Intestinal GLP-1 Levels
- Increased Length
- Increased Leptin Level
- Increased Leptin Levels
- Increased Levels of Beneficial Metabolites
- Increased Lifespan
- Increased Lipid Oxidation
- Increased Lipolysis Activity
- Increased Lumbar Vertebra Bone Mineral Density
- Increased Maximal Incremental Cycling Capacity
- Increased Medium-Chain Acylcarnitines
- Increased Muscle Fat Content
- Increased Nitric Oxide Bioavailability
- Increased Nitric Oxide Metabolite Levels in Metabolic Syndrome Patients
- Increased Nitrogen Degradation Postprandially
- Increased Nrf2 Level
- Increased Oxidative Stress
- Increased Oxygen Consumption in White Adipose Tissue
- Increased PPAR-γ Activity
- Increased Paraoxonase 1 Enzyme Activity
- Increased Physical Activity
- Increased Plasma ApoA-V Levels
- Increased Plasma Glucagon Level
- Increased Plasma Level
- Increased Polyphenol Level
- Increased Pro-inflammatory Cytokine Release
- Increased Proportion with Normalized Hemoglobin A1c
- Increased Reactive Oxygen Species Response
- Increased Relative Abundance of Beneficial Bacteria
- Increased Resistant Starch
- Increased Reversion to Normoglycemia
- Increased Rikenellaceae Abundance
- Increased SCFA Concentration
- Increased SCFA Production
- Increased Sepsis
- Increased Serum Amyloid Protein
- Increased Serum Ferritin Level
- Increased Serum Free Fatty Acid Levels
- Increased Serum Glucose Levels
- Increased Serum High-Molecular Weight Adiponectin
- Increased Serum Insulin Levels
- Increased Serum Triglycerides
- Increased Short Chain Fatty Acid Profiles
- Increased Short Chain Fatty Acids
- Increased Short Chain Fatty Acids (SCFAs) Levels
- Increased Short-Chain Fatty Acid Levels
- Increased Short-Chain Fatty Acid Production
- Increased Short-Chain Fatty Acid-Producing Microbial Population
- Increased Short-Chain Fatty Acid-Producing Microbial Taxa
- Increased Short-Chain Fatty Acids (SCFAs) Contents
- Increased Short-Chain Fatty Acids Concentrations
- Increased Solid Non-Fat Content
- Increased Soluble Receptor of Advanced Glycation End Products
- Increased Thiol Level
- Increased Time to Exhaustion
- Increased Total Thiol Level
- Increased Treatment Effectiveness
- Increased Triglyceride Level
- Increased Tumor Necrosis Factor-Alpha Levels
- Increased Uncoupling Protein 2 Expression
- Increased Uncoupling Protein 2 Level
- Increased Urinary Citrate Level
- Increased Visceral Fat Mass
- Increased Weight
- Increased Weight Loss
- Increased c9t11 CLA Production in Adipose Tissue
- Increased β-Cell Area in Pancreatic Islets
- Induced Health-Related Benefits
- Influence on Metabolic Pathways
- Inhibited Absorption of Advanced Glycation End-products (AGEs)
- Inhibited Lipid Oxidation
- Inhibited α-Amylase Activity
- Lower Plasma Glucose Levels
- Maintained Glucose Control
- Maintained Homeostasis
- Mimicked Dietary Restriction Effects
- Modified Fetal Brain Metabolism
- Modified Serum Metabolomic Pathways
- Modulated Gut Microbiome Composition
- Modulated PPAR/SREBP Pathway
- Multiple Health-Promoting Effects
- No Adverse Safety Findings
- No Adverse Weight or Intake Effects in Mice
- No Change in Body Weight or Cardiometabolic Parameters
- No Change in Body Weight or Food Consumption
- No Change in Ectopic Fat Content
- No Change in HDL Cholesterol
- No Change in High Density Lipoproteins
- No Change in Lipid Profile
- No Change in Metabolic Health
- No Change in Microbial Diversity
- No Change in Serum Triglycerides
- No Difference in Adverse Events
- No Reduction in Meat Cholesterol Levels
- No Significant Change in Growth Performance
- No Significant Effect on C-Reactive Protein Levels
- Normalized Gut Metabolites
- Notable Improvement in Multiple Health Metrics
- Preserved Beta-Cell Function
- Preserved Insulin-Secreting Beta Cells
- Preserved Islet Function
- Prevention of Beta-Cell Loss
- Prevention of Nonalcoholic Fatty Liver Disease
- Prevention of Obesity Transition
- Prevention of Weight Gain
- Promoted Weight Gain
- Protection Against Oxidative Stress
- Reduced Abdominal Fat
- Reduced Adherence Attrition
- Reduced Adipocyte Diameter
- Reduced Adipocyte Hypertrophy
- Reduced Adipocyte Senescence
- Reduced Adipogenesis
- Reduced Adipsin Level
- Reduced Advanced Glycation End Product Level
- Reduced Alpha-Amylase Activity
- Reduced Apelin Gene Expression
- Reduced Apolipoprotein B to A-1 Ratio
- Reduced Arterial Stiffness
- Reduced Atherosclerosis Risk Factors
- Reduced BCG Phagocytic Intake
- Reduced Beta Cell Function
- Reduced Beta-Cell Loss
- Reduced Blood Cholesterol
- Reduced Blood Glucose Level
- Reduced Blood HbA1c Levels
- Reduced Body Fat
- Reduced C-Reactive Protein Level
- Reduced Cancer Incidence
- Reduced Cancer Mortality
- Reduced Candida Albicans Survival
- Reduced Cardiovascular Disease
- Reduced Cardiovascular Disease Risk
- Reduced Cardiovascular Mortality
- Reduced Cardiovascular Risk
- Reduced Cardiovascular Risk Profile
- Reduced Cause-Specific Mortality
- Reduced Cellular Senescence
- Reduced Central Blood Pressure
- Reduced Cerebrovascular Mortality
- Reduced Circulating Endotoxin
- Reduced Common Cold Incidence
- Reduced Community Healthcare Costs
- Reduced Conicity Index
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Contrast-Induced Nephropathy
- Reduced Coronary Heart Disease Risk
- Reduced Cost-Effectiveness in Reducing AAD
- Reduced Cumulative Morbidity Rates
- Reduced De Novo Lipogenesis
- Reduced Diabetes Risk
- Reduced Diabetic Complications
- Reduced Diabetic Ketoacidosis Incidence
- Reduced Diabetic Neuropathic Pain
- Reduced Dietary Advanced Glycation End Product Intake
- Reduced Disease Incidence
- Reduced Disease Progression
- Reduced Disease Severity
- Reduced Dyslipidemia Parameters
- Reduced Dyslipidemia in Metabolic Syndrome
- Reduced ER Stress Responses in β-cells
- Reduced Endoplasmic Reticulum Stress Markers
- Reduced Enzyme Activity Related to Diabetes
- Reduced Exercise-Induced Glucose Levels
- Reduced Fasting Blood Glucose
- Reduced Fasting Blood Glucose Levels
- Reduced Fasting Blood Sugar Levels
- Reduced Fasting Insulin Level
- Reduced Fat Gain
- Reduced Fat-Free Mass
- Reduced Fecal Microbiota Diversity
- Reduced First Phase Insulin Secretion
- Reduced Flavonifractor Abundance
- Reduced Flavonoid Levels
- Reduced Free Fatty Acid Levels
- Reduced GIP
- Reduced Glucagon Pathway Activity
- Reduced Gluconeogenesis
- Reduced Glucose Area Under the Curve
- Reduced Glucose Intolerance
- Reduced Glucose Level
- Reduced Glucose Levels
- Reduced Glucose Uptake
- Reduced Glutathione Loss
- Reduced Glycated Hemoglobin
- Reduced Glycated Hemoglobin A1c Level
- Reduced Glycation End Product Accumulation
- Reduced Glycative Stress Marker Level
- Reduced Glycemic Enzyme Inhibition
- Reduced Glycemic Index
- Reduced Glycemic Response
- Reduced Glycosylated Hemoglobin
- Reduced HDL Cholesterol Level
- Reduced HDL Levels
- Reduced HIF-1α Level
- Reduced HOMA-IR
- Reduced HOMA-β
- Reduced HbA1c Level
- Reduced Hemoglobin A1C Level
- Reduced Hemoglobin A1c
- Reduced Hepatic Glycogen Levels
- Reduced Hepatic Insulin Resistance
- Reduced Hepatic Lipogenesis
- Reduced High-Density Lipoprotein (HDL) Cholesterol
- Reduced High-Density Lipoprotein Cholesterol Level
- Reduced High-Sensitivity C-Reactive Protein
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Homeostatic Model Assessment for Insulin Resistance
- Reduced Hospitalization Duration
- Reduced Hypercholesterolemia Incidence
- Reduced Hyperglucagonemic Response
- Reduced Hyperglycemic Response
- Reduced Hypertension
- Reduced IFN-γ in Serum
- Reduced Immune Cell Proliferation
- Reduced Incidence of Colon Cancer
- Reduced Incidence of Liver Cancer
- Reduced Inflammation in Adipose Tissue
- Reduced Inflammatory Biomarker Level
- Reduced Insulin Output (90-min)
- Reduced Insulin Requirement
- Reduced Insulin Response
- Reduced Insulin Sensitivity
- Reduced Insulin/IGF-1 Signaling
- Reduced Islet β-Cell Dysfunction
- Reduced Lactate Levels
- Reduced Lifespan
- Reduced Lipid Oxidation
- Reduced Lipid Profiles
- Reduced Liver Fat Accumulation
- Reduced Liver Fat Deposition
- Reduced Lymphocytic Genome Damage
- Reduced Lysophosphatidylcholine Level
- Reduced Lysophosphatidylethanolamine 18:1 Level
- Reduced Macrophage Infiltration in Adipose Tissue
- Reduced Malondialdehyde Generation
- Reduced Malondialdehyde Level
- Reduced Medication Requirement
- Reduced Mesenteric Adipose Tissue Accumulation
- Reduced Metabolic Disease Risk
- Reduced Metabolic Disorders Incidence
- Reduced Metabolic Dysregulation
- Reduced Metabolic Endotoxemia
- Reduced Metabolic Function
- Reduced Metabolic Functions of Intestinal Microbiota
- Reduced Metabolic Syndrome
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Mortality Risk
- Reduced Mortality from Frailty
- Reduced Muscle Thickness
- Reduced Mycobacterium bovis BCG Phagocytic Uptake
- Reduced N-terminal Pro-B-type Natriuretic Peptide Level
- Reduced NAFLD Activity Score
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Nitric Oxide Level
- Reduced Non-Communicable Disease Risk
- Reduced Non-HDL Cholesterol
- Reduced Non-High-Density Lipoprotein Cholesterol
- Reduced Non-Infectious Complication Morbidity
- Reduced Obesity Indicators
- Reduced Obesity-Related Microbial Taxa
- Reduced Obesity-Related Taxa
- Reduced Oleic Acid-Induced Triglyceride Accumulation
- Reduced Omission Errors
- Reduced Oxidative Damage
- Reduced Oxidative Stress
- Reduced Oxidative Stress Index
- Reduced Oxidative Stress Marker Level
- Reduced Oxidized Glutathione Level
- Reduced PP4C Expression in Adipose Tissue
- Reduced Pancreatic Inflammatory and Metabolic Dysregulation
- Reduced Pancreatic Stress-Related Pathways
- Reduced Pathogen Resistance
- Reduced Peak Plasma Glucose Level
- Reduced Perinatal Loss
- Reduced Peripheral Neuropathy Grade
- Reduced Plasma CRP Levels
- Reduced Plasma Glucose Levels
- Reduced Plasma Lipopolysaccharide Levels
- Reduced Plasma Non-Esterified Fatty Acid Concentrations
- Reduced Plasma Triglycerides
- Reduced Post-Exercise Serum Amyloid A Increase
- Reduced Postprandial Blood Glucose
- Reduced Postprandial Blood Glucose Level
- Reduced Postprandial Blood Glucose Rise
- Reduced Postprandial Glucose
- Reduced Postprandial Glucose Levels
- Reduced Postprandial Glucose Response
- Reduced Postprandial Glycemia
- Reduced Postprandial Glycemic Response
- Reduced Postprandial Insulin
- Reduced Postprandial Insulin Response
- Reduced Postprandial Triacylglycerol Response
- Reduced Pre-eclampsia
- Reduced Prevalence of Gestational Diabetes Mellitus
- Reduced Pro-inflammatory Biomarker Level
- Reduced Prostate Cancer Risk
- Reduced Protein Carbonyl Levels
- Reduced Protein Glycation
- Reduced Protein Oxidation
- Reduced Rapidly Digestible Starch
- Reduced Recovery Time After Surgery
- Reduced Renal Free-CML
- Reduced Risk of COVID-19 Progression
- Reduced Risk of Coronary Heart Disease
- Reduced S. Enteritidis Invasion
- Reduced SCD1 Activity
- Reduced Salivary Nitrite/Nitrate Levels
- Reduced Serious Adverse Events
- Reduced Serum C-reactive Protein Levels
- Reduced Serum Cholesterol
- Reduced Serum Cholesterol Levels
- Reduced Serum Glucose Levels
- Reduced Serum Glycerophospholipid Levels
- Reduced Serum Inflammatory Factors
- Reduced Small-for-Gestational-Age
- Reduced Soluble Receptor of Advanced Glycation End Product Level
- Reduced Standard Care Medication Need
- Reduced Steatosis Score
- Reduced Sugar Craving
- Reduced Sugar-Sweetened Beverage Intake
- Reduced Symptoms Associated with High-Fat Diet
- Reduced Systemic Endotoxemia at Rest
- Reduced TMAO Level
- Reduced TMAO Levels
- Reduced TMAO Production
- Reduced Total Blood Cholesterol
- Reduced Total Cholesterol to HDL Cholesterol Ratio
- Reduced Total Glucagon-Like Peptide-1 Levels
- Reduced Total Glycated Hemoglobin
- Reduced Total Lipid Levels
- Reduced Total Testosterone Level
- Reduced Treatment Costs
- Reduced Treatment Failure Rate
- Reduced Triglyceride Levels
- Reduced Triglyceridemia
- Reduced Trimethylamine N-oxide Levels
- Reduced Two-Hour Postprandial Glucose
- Reduced Urinary Albumin
- Reduced Very Low-Density Lipoprotein
- Reduced Visceral Fat Area
- Reduced Visceral Fat Mass
- Reduced Visfatin Level
- Reduced Waist Circumference
- Reduced Waist-to-Height Ratio
- Reduced Wound Area
- Reduced Zinc Level
- Reduced hsCRP Level
- Reduced α-Glucosidase Activity
- Regulated Blood Glucose Levels
- Regulated Carbohydrate Metabolism Enzyme Level
- Regulated Gut Microbiota Metabolic Function
- Regulated Hormone Level
- Regulated Lipid Metabolism
- Regulated Lipid Metabolism in Epididymal Fat Pads
- Regulated Microbial Metabolism
- Remission of Metabolic Syndrome
- Remodeled Intestinal Microbiota
- Restored Gut Microbiota Diversity
- Restored HDL Levels
- Restored Lipid Metabolism
- Retina Protection
- Reversed Microbiome Metabolic Changes
- Safe Administration
- Safe for Chronic Consumption
- Stabilized Blood Glucose Level
- Stabilized Hemoglobin A1c Level
- Stabilized Visceral Fat Area
- Stable Antihyperglycemic Effect
- Stable Fasting Blood Sugar Level
- Stable Fasting Plasma Glucose
- Stable Glucose Metabolism Markers
- Stable HDL Cholesterol Levels
- Stable High-Density Lipoprotein Cholesterol Level
- Stable Organ Weight
- Suppressed PPAR/SREBP Pathway Gene Activity
- Suppressed Wnt/β-catenin Signaling
- Sustained Immune Function
- Unchanged Glycemic Control
- Unchanged Insulin Resistance
- Unchanged Plasma Lipid Levels
- Weight Gain Consistency
- Worsened Acidosis